Cite this answer
Epithalon: quick citable summary
Epithalon is listed by PeptaHub as a longevity peptide with a reclassification pending legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Epithalon: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/epithalon. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/epithalon.
What is Epithalon?
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on pineal epithalamin that activates telomerase and stimulates melatonin production. It is not FDA-approved and is sold internationally as a research chemical.
Overview
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural peptide epithalamin, which is produced by the pineal gland. It was discovered by Russian gerontologist Professor Vladimir Khavinson, who spent over 35 years researching peptide bioregulators. It is best known for reports that it activates telomerase and elongates telomeres, though those findings come from cultured human cells rather than from treated people.
Mechanism of action
In telomerase-negative human fibroblast culture, Epithalon induced expression and activity of telomerase — the enzyme that adds telomeric repeats (TTAGGG) to chromosome ends — and elongated telomeres. Whether this happens in a treated person has not been shown. In elderly subjects given the related pineal extract Epithalamin, nighttime melatonin rose in those with low baseline pineal activity and tended to fall in those with normal function, so the effect is better described as modulating pineal output than as simply stimulating it. Khavinson's group proposes it acts as a peptide bioregulator at the level of gene expression and chromatin structure.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| anti-aging / telomerase activation | subcutaneous | 5–10 mg | daily | Typical protocol: 5-10mg daily for 10-20 days, repeated every 4-6 months. Based on Khavinson's clinical protocols. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert Epithalon research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? The Epithalon dose calculator is preloaded with these ranges, or use the general dose unit converter.
Research summary
Khavinson's group reported that adding Epithalon to telomerase-negative human fetal fibroblast culture induced telomerase expression and activity and elongated telomeres (Bull Exp Biol Med 2003) — an in vitro result, not a demonstration in a living person. The main human data come from Khavinson & Morozov (Neuro Endocrinol Lett 2003), a clinical assessment of 266 elderly people followed 6 to 8 years, in which the Epithalamin-treated group had a 1.6 to 1.8-fold lower mortality rate than controls. In elderly subjects, Epithalamin modulated pineal melatonin output, raising nighttime melatonin in those whose pineal activity was low at baseline while tending to lower it in those with normal function (Korkushko et al., Bull Exp Biol Med 2004). Limitations are substantial: the human work is non-randomized, comes from a single research group, is Russian-language, and has not been independently replicated. Most of it also studied Epithalamin, the pineal extract, rather than the synthetic tetrapeptide sold as Epithalon.[1][2][3][4][5][6]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Epithalon for synergistic effects.
Legal status
Epithalon cannot legally be compounded in the US today. It is one of 12 peptides the FDA removed from Category 2 of the interim 503A bulk drug substances list on April 15, 2026, effective within seven calendar days, because the original nominators withdrew their nominations. Removal from Category 2 is not the same as being added to the Section 503A Bulks List or placed in Category 1, and the FDA has been explicit that it does not by itself make a substance eligible for compounding — enforcement discretion extends only to Category 1, and these substances were never in Category 1. The Pharmacy Compounding Advisory Committee took up the substance, which the FDA lists as Epitalon, on July 24, 2026 (docket FDA-2025-N-6895); FDA staff briefing documents recommended against adding it to the Bulks List, citing inconsistent naming conventions among other concerns. PCAC is advisory and formal rulemaking afterward typically takes 12 to 24 months. Epithalamin (the natural extract) is approved in Russia as a pharmaceutical; the synthetic version is not FDA-approved and is otherwise sold as a research chemical internationally. Verify current federal and state rules before relying on access claims.
Sourcing & access
Reclassification in progress
Epithalonis one of 12 peptides the FDA removed from its Category 2 “do not compound” list on April 15, 2026, after the original nominations were withdrawn. That removal did not place it on the 503A Bulks List or into Category 1, so it is not currently eligible for compounding. The Pharmacy Compounding Advisory Committee is reviewing these substances for the Bulks List; adding one requires formal rulemaking, which typically takes 12 to 24 months. See our regulatory status tracker and regulatory timeline for the current position.
Frequently asked questions
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin, a natural extract of the bovine pineal gland. It was developed by Russian gerontologist Vladimir Khavinson, who has studied pineal peptides for over 35 years. Epithalon is the primary synthetic compound from his research program and has been studied for telomerase activation, melatonin regulation, and longevity.
In cultured human fibroblasts, epithalon switched on telomerase — the enzyme that adds TTAGGG repeats to chromosome ends — and lengthened telomeres. It has also been reported to modulate pineal melatonin secretion in elderly subjects, raising it where baseline pineal output was low. From these, a slowing of biological aging is proposed rather than demonstrated: no human study has measured telomere length or a validated aging endpoint in people taking the peptide.
Epithalon is not approved by the FDA or most international regulatory agencies as a drug for any indication. Epithalamin (the natural pineal extract) has been approved in Russia. The synthetic peptide epithalon is sold internationally as a research chemical without prescription. Its legal status for human use varies by country, and it is not classified as a controlled substance in the United States.
Research protocols derived from Khavinson's clinical work typically use 5 to 10 mg per day by subcutaneous or intramuscular injection. Cycle lengths are 10 to 20 consecutive days, repeated every 4 to 6 months. This cyclic protocol is designed to mimic the intermittent pineal peptide exposure observed in biological systems rather than continuous supplementation.
Khavinson & Morozov (Neuro Endocrinol Lett 2003) assessed 266 elderly people over 6 to 8 years and reported a 1.6 to 1.8-fold lower mortality rate in the Epithalamin group than in controls, with larger reductions for thymalin and for the two combined. That is not a randomized controlled trial, it comes from a single research group, it has never been independently replicated, and it tested Epithalamin, the pineal extract, rather than the synthetic tetrapeptide sold as epithalon. Rodent lifespan-extension figures circulate widely for this compound, but we could not verify a specific percentage against a retrievable paper and so do not quote one. On the available evidence, no lifespan claim in humans is supported.
The most commonly reported side effects are injection site discomfort and rare mild flu-like symptoms (fatigue, low-grade fever) during the first 1 to 2 days of a new cycle. Transient drowsiness has been reported. No serious adverse events have been documented in the available literature, but that literature contains no dedicated safety trial with systematic adverse-event collection, so this is an absence of reported harm rather than positive evidence of safety.
Epithalon's plasma half-life is estimated at approximately 2 to 3 hours, though this figure is not precisely characterized in published pharmacokinetic studies. Its short half-life is consistent with other small tetrapeptides and supports the daily injection protocols used in Khavinson's research. The biological effects on gene expression and telomerase activity appear to persist beyond the peptide's plasma clearance.
Research references
- Epithalon peptide induces telomerase activity and telomere elongation in human somatic cellsPubMed
- Peptide Epitalon activates chromatin at the old agePubMed
- AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic MechanismPubMed
- Peptides of pineal gland and thymus prolong human lifePubMed
- Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising PropertiesPubMed
- Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly peoplePubMed